AUSTRALIAN pharmaceutical company Phebra has launched Laceraine, a novel topical anaesthetic gel for open lacerations that was developed and manufactured in Australia.
A combination of lidocaine, tetracaine and adrenaline, the gel is used in frontline health settings across the community, including hospitals, urgent care clinics and general practice.
Phebra CEO Andre Vlok said the development of Laceraine demonstrates the company's longstanding commitment to strengthening Australia's sovereign capability in essential medicines.
"We're extremely proud to be adding Laceraine to Phebra's portfolio of Australian-made medicines to address an unmet need for healthcare professionals and their patients," Vlok said.
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Apr 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Apr 26
